|
|
SAVE
10% AS A CHI CONTACT* |
 |
Now
Available as Part of CHI's
Network of Approved
Reports |
 |
|
|


|
NEW!
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
The Definitive Industry Reference, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal.
"The report sets out to give the reader a full insight into determining valuation and royalties and the huge impact that these terms can have on deals and their ultimate survival."
Dr Fintan Walton,
CEO of PharmaVentures
The content has been formulated by leveraging over 15 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, and in response to valued feedback from our extensive market research. This report follows on from the publication of previous top selling reports on the topic of royalty rates.
- Clear guidance on the best methodologies to use when calculating Royalty Rates to assist with vital decision making
- Opinions and advice from leading industry deal makers on how to calculate Royalty Rates
- Contextual information – The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?”
- More case studies – PharmaVentures highlights the issues and pitfalls so that you can avoid them
Click
here to view the full table of contents
|
|
|
|
|


|
Competition Law and Intellectual Property Strategy in the
Pharmaceuticals Sector
The report, written by Bird
& Bird's leading lawyers, sets out the essential
issues concerning the intellectual property regime and the
application of competition law in the pharmaceuticals sector,
and the sector-specific regulatory provisions affecting
competition.
The resulting case law both at
EU level and at national level implementing the EU rules on
competition and the related regulatory developments are central
to the strategic decisions of pharmaceuticals suppliers.
Looking at leading
cases within the pharmaceuticals sector, involving companies
such as GlaxoSmithKline, Boehringer Ingelheim, Bayer,
Organon, Johnson & Johnson, AstraZeneca, Napp
Pharmaceuticals and Genzyme to
illustrate the key points, the report examines essential issues,
including the following:
- How legislation and case law
has set out limits in various areas on the extents to which
intellectual property owners can enforce their patents
- Parallel importation under
the EC rules on free circulation of goods and the EC
competition rules, agreements and conduct restricting
parallel imports and exports
- Meaning of an agreement
under the EC competition rules
- Conduct of dominant
suppliers with regard to pricing issues
- Commission guidelines on the
application of competition rules to R&D collaboration
agreements
- Effect of regulation on
technology licensing, marketing and distribution agreements
UK and EC competition
authorities' commitment to private enforcement of the
competition rules to combat cartels
Click
here to view the full table of contents
|
|
|
|
|


|
Pricing and Reimbursement: Risk and Opportunity in Pharmaceutical Deal Making
The report
covers those essential market changing initiatives which make
tomorrow’s drug market different from today’s. Successful
deal making has accurate valuation at its heart. Anything that
impacts a drugs ability to achieve in the future a fair and
profitable market price impacts its value today. The current
market is more challenging than ever before. Payer-driven price
negotiation for reimbursement, and cost-containment programmes
to control prescribing both challenge the traditional pricing
model the industry has used to generate valuable R&D
resource to further the search for innovation and better disease
control.
Click
here to view the executive summary
|
|
|
|
|


|
The Pharmaceutical Deals of 2006
- Lessons for 2007
With
analysis of deal making trends, and discussion of the top deals
by therapy area as well as their impact on the market-place, this
resource will be of immense value to those who need to stay
up-to-date on the developments in their area, those planning to
do deals in other therapy areas and those interested in
understanding how the deals made in 2006 are likely to affect their firm's
business strategy in 2007. To add further value, the report is
accompanied by interviews with industry experts.
Access to these interviews will be provided online.
Click
here to view the executive summary
|
|
|
|


|
Valuing and Structuring Pharmaceutical Licensing Agreements
This
publication provides an essential grounding in how to use
accepted and reliable methods for valuing pharmaceutical and
biotech projects. Whether you are about to negotiate a licensing
deal or need to perform a rigorous portfolio review, it is vital
that you understand both the value of a project today and how
that value can be built over time.
The methods
presented here provide answers to both questions through the
combination of historical analysis of what the market has been
willing to pay for similar products and technologies, and
forward-looking projections that explicitly handle the issues of
risk, time, cost and reward.
Potential
elements of deals are also discussed, as are the appropriate
levels of risk and reward sharing, and the significance of
individual company needs and preferences. When incorporated into
the valuation models that have been built, these elements will
permit the development of deal structures that are attractive to
both sides.
Click
here to view the executive summary |
|
|
|


|
Pharmaceutical Deal Structures Report
This
reference guide provides deal makers with answers to many of the
questions that arise in specific deal situations. It is a
comprehensive source of information relating to all deal
structures and is the ultimate reference source for anyone
involved in business development or licensing. Accompanied by an
online access, each specific agreement or structure type is
illustrated with current case studies.
Click
here to view the executive summary |
|
|
|


|
Spotlight Report Series
PharmaVentures publishes a series of reports dedicated to assisting companies in
business development and deal making in the pharmaceutical & healthcare sectors.
Published reports include:
PharmaDeals® Deal Making Spotlight Reports
Deal Making Spotlight on Pfizer
Deal Making Spotlight on sanofi-aventis
Deal Making Spotlight on GlaxoSmithKline
Deal Making Spotlight on Johnson & Johnson
Deal Making Spotlight on Novartis
Detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.
Click
here to view the table of contents |
|
|
|
|

|
Spotlight on Influenza - Separating Fact from Fiction in the Battle Against Influenza
Focusing on the hot topic of influenza, this report offers a topical insight into both the flu virus and the methods being employed to tackle it. From an investigative angle, the report specifically explores the pharmaceutical industry's R&D endeavours in combating the virus, affording a comprehensive insight into key players in the arena. Main areas of focus covered by the report include:
- The virus and its history
- Key industry insight
- An analysis of the market
- Summary of influenza-related deals
View
the table of contents |
|
|
|
|

|
Effective Licensing &
Commercialisation of Drug Delivery Systems 2006
Dedicated to
the drug delivery sector, this report offers a concise and
focused means of assessing and benchmarking drug delivery deal
making activity over the past 9 years. It details valuation
methodologies and explores effective deal structuring to ensure
maximum returns. It is a critical report for all those involved
in deal making across both the pharmaceutical and biotechnology
sectors. This edition provides an up-to-date
perspective of the drug delivery sector. It includes over 1400
drug delivery deals, over 50 drug delivery contracts and the
latest company information.
Click
here to view the executive summary |
|
|
|
|

|
Strategies and Tactics for Successful Partnering
This report
provides in-depth information and practical advice relating to
the partnering process. Based on PharmaVentures' experiences of
working with pharmaceutical and biotechnology companies
worldwide, this comprehensive report provides an insight into
the challenges and rewards of the partnering process. The report
includes quotations documenting industry-partnering experiences,
and is a must read for anyone needing to complete & manage
deals.
Click
here to view the executive summary |
|
|
|
* Discount does not
apply to reports already purchased
|